- Page 1/6
Signal
Opinion
Expert
HOLD
HOLD
Fell to book value, but jumped on Pfizer announcement. Intrinsic value is 60% higher than current value. Fairly indifferent balance sheet. If it can break above $31, could easily go as high as $42. No yield.
SELL
SELL
November 18, 2020
It's been buying back stock, so they don't have any book value. This is not a solid mattress to lie on. Fair market value is about 53% lower than the current price. If we're shifting away from growth to value, this isn't the one to buy.
Show full opinionHide full opinion
It's been buying back stock, so they don't have any book value. This is not a solid mattress to lie on. Fair market value is about 53% lower than the current price. If we're shifting away from growth to value, this isn't the one to buy.
SELL
SELL
November 18, 2020
It's hanging in, but it's been buying back stock and keeping upwards pressure on the price. Not cheap. FANGs in general are rolling over. Same as rollovers of the Nifty Fifty in 1972 and the dot.coms of 2000. Be cautious of this group in general.
Show full opinionHide full opinionIt's hanging in, but it's been buying back stock and keeping upwards pressure on the price. Not cheap. FANGs in general are rolling over. Same as rollovers of the Nifty Fifty in 1972 and the dot.coms of 2000. Be cautious of this group in general.
HOLD
HOLD
November 18, 2020
Trades at 2.5x book, versus Netflix at 20x book. DIS has moved ahead slowly like a value stock, whereas Netflix is having trouble and rolling over. We still haven't seen DIS earnings from streaming. Stock is 57% overvalued. Stock technically broke out. Hang in there, albeit nervously.
SPECULATIVE BUY
SPECULATIVE BUY
November 18, 2020
Can't find all that much wrong, or right, with the stock. Price to book is 8x, so not cheap. Reasonable value for a hypergrowth stock, as it's only 18% overvalued. Technically, $17-17.50 should hold. At that level, could be looking at a nice trade.
Show full opinionHide full opinionCan't find all that much wrong, or right, with the stock. Price to book is 8x, so not cheap. Reasonable value for a hypergrowth stock, as it's only 18% overvalued. Technically, $17-17.50 should hold. At that level, could be looking at a nice trade.
HOLD
HOLD
November 18, 2020
Concerned about the dividend. In the midst of expansion. Need all the market goodwill they can get, so probably won't cut the dividend. Technically, back to good support. Nervously hang in there.
Show full opinionHide full opinionConcerned about the dividend. In the midst of expansion. Need all the market goodwill they can get, so probably won't cut the dividend. Technically, back to good support. Nervously hang in there.
WAIT
WAIT
November 18, 2020
Looks as though it's heading lower. His downside target is $50. When it got there in June, had a nice rebound. Hang on, and add at those levels. In 2021, US deficit is going to be something else, and Fed will have to bail them out. More stimulus is good for gold.
Show full opinionHide full opinionLooks as though it's heading lower. His downside target is $50. When it got there in June, had a nice rebound. Hang on, and add at those levels. In 2021, US deficit is going to be something else, and Fed will have to bail them out. More stimulus is good for gold.
Fell to book value, but jumped on Pfizer announcement. Intrinsic value is 60% higher than current value. Fairly indifferent balance sheet. If it can break above $31, could easily go as high as $42. No yield.